Drugs / LY3200327
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02595736 | Nov 2015 → Aug 2016 | — | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3200327 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02595736 ↗ |
| Route | Subcutaneous | “Administered SC” NCT02595736 ↗ |